참고문헌
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-544. https://doi.org/10.1038/s41564-020-0695-z
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-436. https://doi.org/10.1038/s41586-020-2521-4
- Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis 2021;73:2257-2264. https://doi.org/10.1093/cid/ciab079
- Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 2021;18:298-307. https://doi.org/10.20892/j.issn.2095-3941.2020.0559
- Li Q, Chen L, Li Q, et al. Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission. Leukemia 2020;34:2384-2391. https://doi.org/10.1038/s41375-020-0986-7
- Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21:1309-1316. Erratum in: Lancet Oncol 2020;21:e462. https://doi.org/10.1016/S1470-2045(20)30442-3
- Pinato DJ, Tabernero J, Bower M, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol 2021;22:1669-1680. https://doi.org/10.1016/S1470-2045(21)00573-8
- Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 2021;18:313-319. Erratum in: Nat Rev Clin Oncol 2021;18:320. https://doi.org/10.1038/s41571-021-00487-z
- Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol 2014;8:57-64. https://doi.org/10.4137/CMO.S13774
- Shah MK, Kamboj M. Immunizing cancer patients: which patients? Which vaccines? When to give? Oncology (Williston Park) 2018;32:254-258, C3.
- Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol 2022;15:15. https://doi.org/10.1186/s13045-022-01233-3
- Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 2022;160:243-260. https://doi.org/10.1016/j.ejca.2021.10.014
- Chiarella SE, Jenkins SM, Smith CY, et al. Predictors of seroconversion after coronavirus disease 2019 vaccination. Ann Allergy Asthma Immunol 2022;129:189-193. https://doi.org/10.1016/j.anai.2022.05.026
- Cavanna L, Citterio C, Biasini C, et al. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy. Eur J Cancer 2021;157:441-449. https://doi.org/10.1016/j.ejca.2021.08.035
- Rousseau B, Loulergue P, Mir O, et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 2012;23:450-457. https://doi.org/10.1093/annonc/mdr141
- Keam B, Kim MK, Choi Y, et al. Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 2017;123:841-848. https://doi.org/10.1002/cncr.30468
- National Comprehensive Cancer Network® (NCCN®). Recommendations of the NCCN® advisory committee on COVID-19 vaccination and pre-exposure prophylaxis. NCCN®; 2022.
- European Society for Medical Oncology (ESMO). ESMO statements on vaccination against COVID-19 in people with cancer. Lugano: ESMO; 2021.
- Mulder SF, Jacobs JF, Olde Nordkamp MA, et al. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res 2011;17:4541-4549. https://doi.org/10.1158/1078-0432.CCR-11-0253
- Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol 2021;22:1681-1691. https://doi.org/10.1016/S1470-2045(21)00574-X
- Keam B, Kang CK, Jun KI, et al. Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. Clin Infect Dis 2020;71:422-425. https://doi.org/10.1093/cid/ciz1092
- Centers for Disease Control and Prevention (CDC). Pfizer-BioNTech COVID-19 vaccine reactions & adverse events. Atlanta: CDC; 2021.
- Soyfer V, Gutfeld O, Shamai S, Schlocker A, Merimsky O. COVID-19 vaccine-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys 2021;110:957-961. https://doi.org/10.1016/j.ijrobp.2021.02.048
- Stewart R, McDowell L. Radiation recall phenomenon following COVID-19 vaccination. Int J Radiat Oncol Biol Phys 2021;111:835-836. https://doi.org/10.1016/j.ijrobp.2021.06.023